ASEPA NEWS

ASEPA NEWSLETTERS

 

July 2020 Newsletter

January 2020 Newsletter
July 2019 Newsletter

January 2019 Newsletter

 
 

RECENT NEWS

 

October 11, 2020: 

Highlight of new Freestyle Libre 2 Flash CGM on Danatech 

https://www.danatech.org/continuous-glucose-meters/freestyle-libre-2-flash-glucose-monitoring-system/

** If this link takes you to the danatech login page instead of opening directly, enter your username and password; your browser will then automatically be directed to the above link.

June 18, 2020: 

FDA Approves Lilly's Ultra-Rapid-Acting Insulin, Lyumjev

https://www.medscape.com/viewarticle/932572?nlid=136000_3901&src=wnl_newsalrt_200618_MSCPEDIT&uac=151802MX&impID=2424955&faf=1

June 17, 2020: 

The following poster was presented virtually at the ADA 80th Scientific Sessions held June 12-16, 2020 

The Case for Targeted Diabetes Medication and Device CME for PCPs 

June 17, 2020: 

The following article was published in Diabetes Research and Clinical Practice 

Enhancing resources for healthcare professionals caring for people on intensive insulin therapy: Summary from a national workshop

 

March 24, 2020: 

AACE Position Statement: Coronavirus (COVID-19) and People with Adrenal Insufficiency and Cushing’s Syndrome

https://www.aace.com/recent-news-and-updates/aace-position-statement-coronavirus-covid-19-and-people-adrenal

 

March 9, 2020: 

FDA draft guidance eliminates CV outcomes trial recommendation for diabetes drug approvals

https://www.healio.com/endocrinology/cardiometabolic-disorders/news/online/%7B776cceaa-906d-4ecc-a8ea-e7479c3de9ba%7D/fda-draft-guidance-eliminates-cv-outcomes-trial-recommendation-for-diabetes-drug-approvals

February 15, 2020: 

FDA recall on Medtronic pumps - 600 series

https://www.fda.gov/medical-devices/medical-device-recalls/medtronic-recalls-minimed-insulin-pumps-incorrect-insulin-dosing

February 13, 2020:

FDA voluntary recall of anti-obesity drug Belviq

https://www.fda.gov/safety/medical-product-safety-information/belviq-belviq-xr-lorcaserin-eisai-drug-safety-communication-fda-requests-withdrawal-weight-loss-drug

January 28, 2020:

FDA okays triple-combo pill for type 2 diabetes

https://www.mdedge.com/endocrinology/article/216254/diabetes/fda-okays-triple-combo-pill-type-2-diabetes

January 21, 2020: 

FDA approves first treatment for thyroid eye disease 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease

 

January 16, 2020:

FDA Approves Semaglutide Injection for Cardiovascular Risk Reduction

https://www.mdmag.com/medical-news/fda-semaglutide-injection-ozempic-cardiovascular-reduction

January 6, 2020:

Fiasp is now approved for children with diabetes

https://www.healio.com/endocrinology/diabetes/news/online/%7B4fc7dab7-a67b-4e15-84ac-f534bbc2b3ca%7D/fda-approves-rapid-acting-insulin-for-children-with-diabetes

 

December 13, 2019:

FDA approves Tandem Diabetes Care Control IQ Technology, a integrated insulin pump + continuous glucose sensor

https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-interoperable-automated-insulin-dosing-controller-designed-allow-more-choices

 

October 22, 2019: 
FDA OKs Faster-Acting Insulin Aspart for Pump Use (Fiasp)

medscape.com/viewarticle/920162

 

October 21, 2019: 
FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes (Farxiga)

medscape.com/viewarticle/920093

 

September 30, 2019: 
FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease (Invokana)

medscape.com/viewarticle/919184

 

 

CMHC’s Monthly Newsletter:
cardiometabolichealth.org/newsletter.html

MEETINGS

 

ASEPA members meet twice a year at the following conferences: AAPA and AACE. We also meet informally at the MEDS East and MEDS West conferences.

 

Throughout the year, board members communicate frequently via email and conference calls. 

CONTACT US

We welcome your feedback! For more information, questions, suggestions for the website, or if you are interested in precepting students, contact us at ASEPAemail@gmail.com 

 

You may also reach out to us below:

ASEPA

281 E Colorado Blvd
PO Box 1145
Pasadena, CA 91102